Aripiprazole Lauroxil
ApprovedTerminated 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Schizophrenia
Conditions
Schizophrenia
Trial Timeline
Jan 23, 2024 → Mar 3, 2025
NCT ID
NCT05662306About Aripiprazole Lauroxil
Aripiprazole Lauroxil is a approved stage product being developed by Alkermes for Schizophrenia. The current trial status is terminated. This product is registered under clinical trial identifier NCT05662306. Target conditions include Schizophrenia.
What happened to similar drugs?
20 of 20 similar drugs in Schizophrenia were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
20
Activity
0
Company
12
Novelty
0
Community
0
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05662306 | Approved | Terminated |
| NCT02636842 | Phase 1 | Completed |
| NCT02634320 | Approved | Completed |
| NCT02320032 | Phase 1 | Completed |
Competing Products
20 competing products in Schizophrenia